Literature DB >> 25996044

Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.

Drew A Spencer1, Jacob S Young, Deepak Kanojia, Julius W Kim, Sean P Polster, Jason P Murphy, Maciej S Lesniak.   

Abstract

Malignant glioma is a relentless burden to both patients and clinicians, and calls for innovation to overcome the limitations in current management. Glioma therapy using viruses has been investigated to accentuate the nature of a virus, killing a host tumor cell during its replication. As virus mediated approaches progress with promising therapeutic advantages, combination therapy with chemotherapy and oncolytic viruses has emerged as a more synergistic and possibly efficacious therapy. Here, we will review malignant glioma as well as prior experience with oncolytic viruses, chemotherapy and combination of the two, examining how the combination can be optimized in the future.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25996044      PMCID： PMC4446703          DOI： 10.4155/tde.14.123

Source DB:  PubMed          Journal:  Ther Deliv        ISSN： 2041-5990


  127 in total

1.  Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

Authors:  W P Roos; L F Z Batista; S C Naumann; W Wick; M Weller; C F M Menck; B Kaina
Journal:  Oncogene       Date:  2006-07-03       Impact factor: 9.867

2.  Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.

Authors:  Stuart A Grossman; Xiaobu Ye; Glenn Lesser; Andrew Sloan; Hetty Carraway; Serena Desideri; Steven Piantadosi
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

3.  Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.

Authors:  K-W Peng; R Myers; A Greenslade; E Mader; S Greiner; M J Federspiel; A Dispenzieri; S J Russell
Journal:  Gene Ther       Date:  2012-04-05       Impact factor: 5.250

4.  Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.

Authors:  Ryuichi Kanai; Cecile Zaupa; Donatella Sgubin; Slawomir J Antoszczyk; Robert L Martuza; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.

Authors:  Ilkka Liikanen; Laura Ahtiainen; Mari L M Hirvinen; Simona Bramante; Vincenzo Cerullo; Petri Nokisalmi; Otto Hemminki; Iulia Diaconu; Sari Pesonen; Anniina Koski; Lotta Kangasniemi; Saila K Pesonen; Minna Oksanen; Leena Laasonen; Kaarina Partanen; Timo Joensuu; Fang Zhao; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2013-04-02       Impact factor: 11.454

Review 6.  Replicative adenoviruses for cancer therapy.

Authors:  R Alemany; C Balagué; D T Curiel
Journal:  Nat Biotechnol       Date:  2000-07       Impact factor: 54.908

7.  Novel integrating adenoviral/retroviral hybrid vector for gene therapy.

Authors:  Stephen J Murphy; Heung Chong; Stephen Bell; Rosa Maria Diaz; Richard G Vile
Journal:  Hum Gene Ther       Date:  2002-04-10       Impact factor: 5.695

Review 8.  Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

Authors:  Samuel T Workenhe; Karen L Mossman
Journal:  Mol Ther       Date:  2013-10-19       Impact factor: 11.454

9.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank J Attenello; Khoi Than; Alessandro Olivi; Jon D Weingart; Henry Brem; Alf Redo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

10.  Glioblastoma multiforme therapy and mechanisms of resistance.

Authors:  Yulian P Ramirez; Jessica L Weatherbee; Richard T Wheelhouse; Alonzo H Ross
Journal:  Pharmaceuticals (Basel)       Date:  2013-11-25
View more
  6 in total

Review 1.  Advances in Immunotherapies for Gliomas.

Authors:  Michael Zhang; John Choi; Michael Lim
Journal:  Curr Neurol Neurosci Rep       Date:  2022-02-02       Impact factor: 6.030

2.  Retargeted adenoviruses for radiation-guided gene delivery.

Authors:  S A Kaliberov; L N Kaliberova; H Yan; V Kapoor; D E Hallahan
Journal:  Cancer Gene Ther       Date:  2016-08-05       Impact factor: 5.987

Review 3.  Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.

Authors:  Wojciech K Panek; J Robert Kane; Jacob S Young; Aida Rashidi; Julius W Kim; Deepak Kanojia; Maciej S Lesniak
Journal:  Oncotarget       Date:  2017-09-11

4.  A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.

Authors:  Julius W Kim; Jason Miska; Jacob S Young; Aida Rashidi; J Robert Kane; Wojciech K Panek; Deepak Kanojia; Yu Han; Irina V Balyasnikova; Maciej S Lesniak
Journal:  Mol Ther Oncolytics       Date:  2017-05-06       Impact factor: 7.200

5.  Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.

Authors:  Wei Wu; Jessica L Klockow; Michael Zhang; Famyrah Lafortune; Edwin Chang; Linchun Jin; Yang Wu; Heike E Daldrup-Link
Journal:  Pharmacol Res       Date:  2021-07-21       Impact factor: 10.334

Review 6.  Oncolytic Viruses for Malignant Glioma: On the Verge of Success?

Authors:  Yogesh R Suryawanshi; Autumn J Schulze
Journal:  Viruses       Date:  2021-07-02       Impact factor: 5.048
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.